Related Experiment Video

Updated: Jun 21, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Mechanism-based treatments for Alzheimer's disease

Peter Davies1, Jeremy Koppel

  • 1Litwin-Zucker Center for Research on Alzheimer's Disease, Feinstein Institute for Medical Research, Manhasset, NY 11030, USA. pdavies@nshs.edu

Dialogues in Clinical Neuroscience
|July 10, 2009
PubMed

Insights

New Alzheimer

Area of Science:

  • Neurology and Pharmaceutical Sciences
  • Alzheimer's Disease Pathogenesis and Therapeutics

Background:

  • Current Alzheimer's disease (AD) treatment landscape is evolving with novel therapeutic strategies.
  • Understanding AD pathogenesis is crucial for developing effective disease-modifying therapies.
  • Existing treatments primarily manage symptoms; new drugs aim to slow or halt disease progression.

Purpose of the Study:

  • To review current theories and emerging therapeutic approaches for Alzheimer's disease.
  • To discuss the challenges and potential of novel drug development targeting AD.
  • To provide an overview of the pipeline for Alzheimer's disease treatments.

Main Methods:

  • Review of current scientific literature on Alzheimer's disease pathogenesis.
  • Analysis of emerging therapeutic targets including beta-amyloid, neurofibrillary tangles, and inflammation.
  • Discussion of clinical trial progress for new Alzheimer's disease drugs.

Main Results:

  • Several new drug candidates targeting different aspects of AD are in clinical trials.
  • Therapeutic strategies focus on beta-amyloid, neurofibrillary tangles, and neuroinflammation.
  • Each therapeutic approach faces unique challenges that need to be addressed.

Conclusions:

  • The development of effective Alzheimer's disease treatments is progressing rapidly.
  • Multiple therapeutic avenues show promise, offering hope for future disease modification.
  • Continued research and clinical trials are essential to identify successful treatments.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...